Risk of Fixed Drug Eruption with Piroxicam (26 Sep 2022) On 26 Sep 2022, PvPI identified the Risk of Fixed Drug Eruption […]
Blog Archive
0
REMS Updates for September and October 2021
REMS Updates for September and October 2021 Here you can find REMS Updates for September and October 2021 REMS Updates for September […]
0
Increased risk of angioedema with vildagliptin and ACE inhibitors
Increased risk of angioedema with vildagliptin and ACE inhibitors In March 2021, Medsafe, the New Zealand Medicines and Medical Devices Safety Authority […]
0
Summary of key health product safety information from Health Canada InfoWatch newsletter
Summary of key health product safety information from Health Canada InfoWatch newsletter This is a monthly publication and is intended primarily for […]
1
Risk of thrombocytopenia and coagulation disorders with the use of COVID-19 Vaccine AstraZeneca
Risk of thrombocytopenia and coagulation disorders with the use of COVID-19 Vaccine AstraZeneca European Medicines Agency (EMA) has published Direct healthcare professional […]
0
Risk of Severe Cutaneous Adverse Reactions (SCARs) with atezolizumab
Risk of Severe Cutaneous Adverse Reactions (SCARs) with atezolizumab 25 MArch 2021: European Medicines Agency (EMA) has published Direct healthcare professional communication […]
0
Risk of serious liver failure with Ulipristal
Risk of serious liver failure with Ulipristal On 18 February 2021, MHRA issued drug safety update on Ulipristal acetate 5mg (Esmya). Esmya […]
0
EMA issued DHPC for Lomitapide
European Medicines Agency (EMA) has published Direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the […]
0
PRAC recommendations on signals
On 8 February 2021, Pharmacovigilance Risk Assessment Committee (PRAC) provided recommendations on the signals discussed during the meeting of 11-14 January 2021. […]
0
Potential Risk of Encephalopathy using Ceftriaxone-containing products (Health Canada)
On 03 February 2021, Health Canada issued a Summary Safety Review of potential risk of encephalopathy using Ceftriaxone-containing products. This review was […]
